• Explore /
  • Poster
  • / Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings.

Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings.

Abstract Poster

Authors

null

Jinan Liu

GlaxoSmithKline, Navy Yard, PA

Jinan Liu, Premal H. Thaker, Janvi Sah, Eric M Maiese, Linda Kalilani, Rajesh Mallampati, Jean Hurteau, John Chan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care

Track

Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 290)

DOI

10.1200/JCO.2020.39.28_suppl.290

Abstract #

290

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Elena Ioana Braicu

First Author: Vaibhav Sahai

First Author: Jean Emmanuel Kurtz

First Author: Philipp Harter